SCHEMBL4955191

SCHEMBL4955191

NCCCC[C@H](NC(=O)OCc1ccccc1)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 4/20 0.71
DPP4 P27487 3/20 0.71
ACE P12821 7/20 0.66
DPP7 Q9UHL4 2/20 0.62
ACE2 Q9BYF1 1/20 0.53
PRSS8 Q16651 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9040814 1.00 DPP8 (0.71) DPP8DPP4ACEDPP7ACE2
SCHEMBL9040522 0.97 DPP4 (0.67) DPP8DPP4ACEDPP7ACE2
SCHEMBL9040510 0.97 DPP4 (0.67) DPP8DPP4ACEDPP7ACE2
Methanesulfonamide SCHEMBL11099377 0.95 DPP8 (0.65) DPP8DPP4ACEDPP7ACE2
SCHEMBL7326774 0.93 DPP8 (0.70) DPP8DPP4ACEDPP7ACE2
Trifluoroacetic Acid SCHEMBL11102587 0.91 DPP4 (0.60) DPP8DPP4ACEDPP7ACE2
SCHEMBL7264291 0.90 DPP8 (0.66) DPP8DPP4ACEDPP7ACE2
Hydrochloric Acid SCHEMBL7264261 0.89 DPP8 (0.65) DPP8DPP4ACEDPP7ACE2
SCHEMBL9692365 0.89 DPP8 (0.57) DPP8DPP4ACEDPP7ACE2
SCHEMBL7322510 0.89 ACE (0.75) DPP8DPP4ACEDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249016-A1 Use of GLP-2 in a combination treatment for bone-related disorders SANOS BIOSCIENCE A/S 2008-10-09 US disclosed
US-7371721-B2 Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes SANOS BIOSCIENCE A/S (DK) 2008-05-13 US disclosed
US-20070135345-A1 Use of GLP-2 for the treatment or prevention, of bone-related disorders SANOS BIOSCIENCE A/S (DK) 2007-06-14 US disclosed
US-7186683-B2 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders SANOS BIOSCIENCE A/S (DK) 2007-03-06 US disclosed
US-20050282749-A1 Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes SANOS BIOSCIENCE A/S 2005-12-22 US disclosed
US-6770620-B2 ADMINISTERING POLYPEPTIDE; BONE DISORDERS SANOS BIOSCIENCE A/S (DK) 2004-08-03 US disclosed
EP-1414486-A2 USE OF GLP-2 IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT IN BONE-RELATED AND NUTRITION-RELATED DISORDERS Osteometer Biotech AS (DK) 2004-05-06 EP disclosed
US-20040052862-A1 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders SANOS BIOSCIENCE A/S (DE) 2004-03-18 US disclosed
US-20020037836-A1 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders SANOS BIOSCIENCE A/S (DK) 2002-03-28 US disclosed
WO-2002024214-A2 USE OF GLP -2 IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT IN BONE-RELATED AND NUTRITION-RELATED DISORDERS OSTEOMETER BIOTECH A/S (DK) 2002-03-28 WO disclosed
EP-0523449-B1 Reductive amination of an aminoacid or an aminoacid derivative with an alpha-keto acid or an alpha-keto acid derivative DEGUSSA (DE) 1996-05-15 EP disclosed
EP-0279750-B1 AMINOACID DERIVATIVES AS ANTIHYPERTENSIVES Asahi Breweries, Ltd. (JP) 1993-01-20 EP disclosed
EP-0523449-A2 Reductive amination of an aminoacid or an aminoacid derivative with an alpha-keto acid or an alpha-keto acid derivative DEGUSSA AG (DE) 1993-01-20 EP disclosed
EP-0190852-A2 Dipeptide derivatives and antihypertensive drugs containing them AJINOMOTO CO., INC. (JP) 1986-08-13 EP disclosed
EP-0132304-A2 Hydroxy substituted peptide compounds E.R. Squibb & Sons, Inc. (US) 1985-01-30 EP disclosed